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ABSTRACT 
Objective: To examine risk factors for Mild Cognitive Impairment (MCI) and progression to 
dementia in a prospective community-based study of subjects aged 65 years and over.  
Methods: Participants were 6892 persons over 65 without dementia recruited from a 
population-based cohort in three French cities. Cognitive performance, clinical diagnosis of 
dementia and clinical and environmental risk factors were evaluated at baseline and 2 and 4 
year follow-up.  
Results: Forty two percent of the population were classified as MCI at base-line. Adjusting 
for confounding with logistic regression models we observed that men and women classified 
as MCI are more likely to have depressive symptomatology and to take medication with 
anticholinergic effects. Men are also likely to have higher BMI, diabetes and stroke whereas 
women are more likely to have poor subjective health, to be disabled, to be socially isolated 
and to suffer from insomnia. The principal adjusted risk factors for men for progression from 
MCI to dementia in descending order are ApoE4 allele (OR=3.2, CI 1.7-5.7), stroke (OR=2.8, 
CI 1.2-6.9), lower education (OR=2.3, CI 1.3-4.1), IADL loss (OR=2.2, CI 1.1-1.2) and age 
(OR=1.2, CI 1.1-1.2). In women progression is best predicted by IADL loss (OR=3.5, CI 2.1-
5.9), ApoE4 allele (OR=2.3, CI 1.4-4.0), low education (OR=2.2, CI 1.3-3.6), sub-clinical 
depression (OR=2.0, CI 1.1-3.6), anti-cholinergic medication use (OR=1.8, CI 1-3), and age 
(OR=1.1, CI 1.1-1.2).  
Conclusions: Men and women have different risk profiles both for a diagnosis of MCI and 
progression to dementia. Intervention programs should focus principally on risk for stroke in 
men and depressive symptomatology and anticholinergic medication use in women. 
 2
INTRODUCTION 
The identification of elderly persons with cognitive impairment at high risk of evolving 
towards Alzheimer’s disease is important for early treatment. The concept of Mild Cognitive 
Impairment
1
 is now widely used to describe this high-risk group and numerous research 
programmes have been undertaken with a view to therapeutic intervention aimed at reducing 
dementia incidence. As MCI is not by definition a very disabling condition, most cases do not 
consult specialists. The clinical characterization of MCI and its related risk factors are thus 
best obtained from general population studies which cover the entire population at risk and 
not just the sub-set of MCI patients coming to specialist centres. Epidemiological studies 
which have included specialist examinations have also shown that while clinical cohorts have 
high rates of progression to dementia, the application of criteria used in this context to the 
general population leads to the exclusion of many cases of MCI considered by clinicians to be 
at high risk
2-5
. Furthermore, as population studies of MCI have shown that most persons with 
MCI will not develop dementia even after 8 years follow-up
2, 5-7
, it is important to determine 
from epidemiological studies the clinical and environmental risk factors for progression from 
MCI to dementia in order to identify cases likely to benefit from treatment, and to target 
appropriate clinical intervention points.  
 
Clinical studies of MCI characterize it principally as a drop in performance on tests of delayed 
recall and executive functioning, linked to hippocampal atrophy mid-way between normal 
ageing and dementia 
8
. Post-mortem studies also indicate that the degree of cognitive 
impairment is proportional to the degree of neurofibrillary pathology in the medial temporal 
lobes 
9
. A number of clinical and population studies have compared MCI and normal cohorts 
prospectively, from which the principal conclusion has been that the risk factors for MCI and 
for MCI progression to dementia are principally the same as those for Alzheimer’s disease 
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(notably age, ApoE4 allele and hypertension)
4, 10
. A major short-coming of all these studies is 
that the clinical measures and environmental risk factors examined in population studies have 
been largely limited to those for Alzheimer’s disease, so that a more general characterization 
of the clinical syndrome of MCI or of its associated risk factors has not been possible. Clinical 
studies on the other hand have been based on MCI subjects referred to specialist centres rather 
than general practice, and therefore unlikely to be representative of all cases of MCI. Finally, 
although most studies adjust by sex in multivariate analyses, they have not examined the 
possibility that risk profiles in MCI may not be the same for men and women.  
 
The present study, based on a large multi-centre prospective population study of brain ageing, 
aims to describe the MCI syndrome by reference to a much wider range of health and 
environmental variables than has previously been considered. Risk factors for MCI and for 
progression from MCI to dementia are examined separately for men and women.  
 
METHODS 
Study population 
Subjects for the present study were recruited randomly from the electoral roles of three 
French cities (Bordeaux, Dijon and Montpellier) between 1999 and 2001 as part of a multi-
site cohort study of community-dwelling persons aged 65 years and over (the Three City 
Study). Subjects were interviewed initially either at a study centre or in their own homes if 
disabled. The cohort was followed up twice at two year intervals. The mortality rate over the 
four year follow-up was 6.8 %. The study design has been described in detail elsewhere
11
. 
The study protocol was approved by the Ethical Committee of the University-Hospital of 
Bicêtre (France) and written informed consent was obtained from each participant. The 
present analysis is carried out on the 6892 subjects (74% of the subjects initially recruited at 
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base-line) who did not have dementia and for whom four-year follow-up data was obtained on 
all variables. The mean age (SD) of the sample was 74.0 (5.5) for men and 74.3 (5.6) for 
women.  
 
Diagnosis of Mild Cognitive Impairment and Dementia 
In a previous report we observed difficulties with the application of the original criteria for 
MCI developed within a clinical setting, to community studies 
5
. Subsequent revision of these 
criteria by an international consensus group
12
  has led to the development of a diagnostic 
algorithm which has high discriminability within the general population setting
13
. The revised 
criteria (MCI-R) are thus applied in this study. These are (i) presence of a cognitive complaint 
from either the subject or a family member (ii) absence of dementia (iii) change from normal 
cognitive functioning (iv) decline in any area of cognitive functioning (v) preserved overall 
general functioning but may be increasing difficulty in the performance of activities of daily 
living. Subjects were asked about their cognitive functioning as part of the general 
examination and difficulties and decline in specific cognitive domains were noted. Each 
participant in the study named a family member as proxy; cognitive difficulties reported by 
proxies were also recorded.   
The cognitive tests used for the definition of MCI-R were the Benton Visual Retention test 
(BVRT) 
14
, the Trail Making Test (TMTB)
15
, the Isaacs' Set Test 
16
 and a word recall test with 
both delayed free recall and recall with semantic prompts 
17
. These tests covered declarative 
verbal and spatial memory, central executive, and semantic retrieval abilities. The National 
Adult Reading Test (NART)
18
 was used as a marker of intelligence. Standardization data was 
obtained by establishing quartile range by age (ten year age groups) and education (primary, 
secondary and tertiary levels) for the entire population. Cognitive impairment was defined as 
having a score (in at least one cognitive test) in the lowest quartile range in relation to the 
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relevant age and education matched comparison group. A preliminary diagnosis and 
classification of dementia at each follow-up examination was made by the 3C study local 
clinical investigators according to DSM-IV revised criteria
19
 , and validated by a national 
panel of neurologists independently of the 3C investigators. 
  
Socio-demographic and clinical variables 
A standardized interview included questions on demographic characteristics, education level 
(classified into three groups corresponding to primary, secondary and tertiary levels of 
education), physical activities, weight and height. Information was also obtained on exposure 
to anaesthesia in the preceding year, subjectively evaluated health, sleep quality, herpes 
infections, subjective report of appetite loss, self-reported social isolation, current alcohol 
consumption, coffee and tea consumption (over 2 cups per day) and tobacco use (packets per 
year). Blood pressure was measured twice during the interview using a digital electronic 
tensiometer OMRON M4. Subjects were considered as hypertensive if mean systolic blood 
pressure was 160mm Hg or higher or mean diastolic blood pressure was 95mm Hg or higher 
or they were on antihypertensive medication. Fasting blood samples were taken for 
cholesterol and glucose levels and apolipoprotein E status. Hypercholesterolemia was defined 
as CST > 6.2 mmol/l) and diabetes as treated diabetes or fasting blood 
 
glucose 7.2 mmol/l. 
Cardiovascular antecedents included history of myocardial infarction, coronary surgery, 
coronary angioplasty, arterial surgery of the legs due to arteritis in inferior limbs. Impairment 
in the performance of everyday activities was assessed with the Instrumental Activities of 
Daily Living Scale (IADL), impairment being defined as increased difficulty in at least one 
IADL 
20
.  
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Past history of head trauma, respiratory disease, cancer, hypertension, hypercholesterolemia, 
diabetes, stroke, asthma, angina pectoris was established according to standardized questions 
with additional information where necessary from general practitioners. For persons who 
reported the occurrence of vascular events during follow-up, further medical data were 
obtained from general practitioners, specialists and hospital records. The interview also 
included an inventory of all drugs used during the preceding month, noting those with 
potential anticholinergic effects according to previously established criteria 
21
, and past as 
well as present use of hormonal replacement therapy (HRT). Medical prescriptions and, 
where feasible, the medications themselves were seen by the interviewer. Depressive 
symptomatology was assessed by the Center for Epidemiological Studies-Depression scale 
(CES-D)
22
 with a >16 cut-off point indicating a high level of symptomatology. Current major 
depressive episode (MDE) was assessed using the Major Depressive Episode module of the 
Mini International Neuropsychiatric Interview (MINI, French version 5.00) according to 
DSM-IV criteria 
23
. Sub-clinical depression was defined by a high level of depressive 
symptomatology without current major depression
 
 
Statistical analyses  
Regression modelling procedures were carried out with SPSS for Windows NT, version 15.0 . 
Forward, stepwise logistic regression was carried out on variables found to be significant on 
univariate analysis. A correlation matrix was used to check colinearity (r>0.80). Interactions 
between variables were also examined. Significant interaction with sex on a large number of 
variables justified our decision to examine risk profiles separately for men and women. Using  
this stratification we have developed additive models, which are easier to interpret. All 
models have been adjusted by study centre. 
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Results 
Following application of MCI-R criteria, 2882 subjects (42%) were classified as having MCI 
at base-line. Thirty six percent of MCI subjects were over 75 years of age and 65% women. 
Of these 189 (6.6%) were diagnosed with dementia over the next four years, 1626 (56.5%) 
remained MCI and 1067 (37%) returned to normal levels of functioning. Significant (p<0.02) 
differences in outcome were observed for men and women; women being less likely to return 
to normal cognitive functioning (36% compared to 39% for men) and to have continuing 
cognitive disorder (58 %, compared to 53% for men).  Eight percent of men with MCI 
developed dementia compared to 6% for women. With regard to type of dementia, 122 MCI 
subjects developed Alzheimer’s disease (AD), 19 vascular dementia, 4 Lewy Body dementia 
and 44 other forms of dementia. Given the small numbers with non-AD dementia, sub-groups 
are mixed in subsequent analyses. Univariate comparisons of subjects with MCI at base-line 
with subjects without cognitive deficit (either at baseline or follow up) are given in Table 1. 
MCI subjects were principally female, older, with lower education levels, having a history of 
diabetes, hypertension, cardiovascular antecedents, stroke, major and sub-clinical depression, 
recent anaesthesia, less physical activity, poorer subjective physical health, insomnia, higher 
BMI, appetite loss, social isolation and IADL difficulties. Women with MCI were less 
frequently HRT users. 
 
Table 1 here 
 
Logistic regression was used to differentiate the principal characteristics of MCI and non-
MCI subjects. Compared to the non-MCI population, men classified as MCI are older, have 
more depressive symptoms, higher BMI, are more likely to have had diabetes and stroke, and 
to take medication with anticholinergic effects. Women with MCI are also more likely than 
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women without MCI to have depressive symptomatology and to take medication with 
anticholinergic effects. Additionally they are more likely to be disabled, to be socially 
isolated, suffer from insomnia and to rate their health as poor (Table 2).  
 
Table 2 here 
 
 
Table 3 shows the clinical and socio-demographic characteristics of MCI subjects according 
to whether they evolved towards dementia (Group 1), remained MCI (Group 2) or returned to 
normal cognitive functioning (Group 3). The significant risk factors associated with 
progression from MCI to dementia are age, low education, hypertension, diabetes, stroke, sub-
clinical depression, anti-depressant use, ApoE4 genotype, low intelligence, use of anti-
cholinergic medication, poor subjectively evaluated health, appetite loss, social isolation and 
difficulties with at least one IADL and women were less frequently HRT users.  
 
 
Table 3 here 
 
 
Significant risk factors derived from the univariate analysis were then entered into a logistic 
regression model predicting MCI progression to dementia versus MCI remaining stable or 
returning to normal for men and women separately (Table 4). For men significant effects were 
observed for higher age, low education, IADL loss, ApoE4 allele, and stroke. For women 
significant effects were found for higher age, low education, IADL loss and ApoE4 allele. In 
women significant effects are also observed for sub-clinical depression and anti-cholinergic 
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medication use (principally psychotropics 43 %); stroke on the other hand is not a significant 
risk factor for women. This difference is not due to differing prevalence of these conditions in 
men and women.  
 
Table 4 here 
 
DISCUSSION 
The principal strengths of the present study have been the examination of a much wider range 
of clinical characteristics and risk factors for MCI than has previously been studied and 
inclusion of a much more heterogeneous sample of MCI cases within this large prospective 
population study than would be expected from clinical studies. Prospective clinical 
examination by neurologists has permitted the identification of “true” MCI cases (that is those 
progressing to dementia or remaining MCI as opposed to those returning to normal 
functioning). Using MCI criteria revised for general population use we estimate MCI 
prevalence at 42%, with relatively high consistency between centres (Bordeaux 43%, Dijon 
47% and Montpellier 28%). The lower rates of MCI in Montpellier, which is in the southern 
Mediterranean region of France, are consistent with lower prevalence of dementia, 
hypertension, stroke and obesity in this region compared to Bordeaux and Dijon in the west 
and north 
11
. The overall prevalence rates are higher than those reported by previous 
population studies using MCI revised criteria (3-25%)
2, 6, 7, 13
 but the catchment area is much 
wider and the sample much larger (6892 subjects compared to previous studies of 581 to 1790 
subjects), thus methodologically likely to be more representative of the community-dwelling 
population and to be in naturalistic conditions of general practice, that explain the low annual 
conversion rate to dementia.  
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The main finding is that MCI cases within the general population may be differentiated by a 
much larger number of socio-demographic and clinical factors than have been previously 
observed and that risk factors for both a diagnosis of MCI and progression from MCI to 
dementia over four years are not the same for men and women. Comparing MCI and non-
MCI subjects in this general population sample, similar differences to those found in previous 
studies were observed; MCI subjects being principally female, older, with lower education 
levels, having depressive symptoms and hypertension. We did not, however, find a higher 
prevalence of ApoE4 allele in the MCI group. Our study was able to identify further 
environmental and clinical risk factors for MCI ; namely a history of diabetes, cardiovascular 
antecedents, stroke, recent anaesthesia, major and sub-clinical depression, lower IQ, anti-
cholinergic medication use, lower caffeine, tobacco and alcohol consumption, less physical 
activity, poorer subjective physical health, insomnia, higher BMI, appetite loss, social 
isolation, IADL difficulties and women were less frequently HRT users.  
 
Multi-variate analysis suggests, however, that after taking into account all possible 
confounding variables and interactive effects the principal characteristics differentiating MCI 
and non-MCI subjects are not the same for men and women. These findings support the 
notion that MCI is a common end-point to multiple aetiological pathways 
24
 which are not the 
same for men and women. These differences in MCI profiles may in part be modulated by 
endocrinological risk factors as well as differences in exposure to environmental hazards such 
as life events, diet and injury. Some studies reports gender differences in dementia risk 
factors
25-27
, but large clinical trials have not yet be designed to included women and men in 
numbers sufficient for assessment of gender effect in the field of MCI. 
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Four years after the base-line assessment 62.7% of subjects classified as MCI are seen to 
either remain cognitively impaired or to progress towards dementia, suggesting that most of 
the subjects classified as MCI do indeed have chronic cognitive problems. The rate of 
progression to dementia is low in this study (6.7%), perhaps due to the short follow-up period 
and non-inclusion of subjects at base-line living in institutions. The principal characteristics of 
subjects progressing from MCI to dementia over a four year period were consistent with 
previous findings; namely age, education, hypertension, antecedents of cardiovascular 
disease, stroke, depression, ApoE4 genotype, low intelligence and difficulties in the 
performance of everyday activities. This much broader study of health factors influencing 
cognitive performance has also identified diabetes, use of anti-cholinergic medication, use of 
HRT for women, poor subjectively evaluated health, appetite loss, social isolation and 
increasing difficulties with at least one everyday activity as being significantly associated 
with poor prognosis. It is interesting to note that while the ApoE4 allele does not differentiate 
normal and MCI subjects at the level of diagnosis, it does differentiate them in terms of 
prognosis. Many of these factors are clearly inter-related, such that taking confounding effects 
into account the principal risk factors for dementia emerge as being in descending order of 
importance ApoE4 allele, stroke, low education,  IADL difficulties and age for men and 
IADL difficulties, ApoE4 allele, low education, and depressive symptomatology, use of 
anticholinergic medication and age for women.  
 
A large number of elderly persons have  stable MCI and it is interesting to note in terms of 
cognitive reserve theory that there are fewer subjects with low levels of education in this 
group compared to those who developed dementia within the four year period. Further follow-
up of this cohort will allow us to differentiate pre-dementia subjects from a probably more 
heterogeneous group of persistent non-dementing MCI and to examine more closely the 
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causes of long-term cognitive impairment. Over a third of MCI subjects were observed to 
return to normal levels of functioning. The same proportion has been reported by a previous 
population study 
3
. Adjusting for confounders the principal factors determining a move in this 
direction were seen to be lower BMI for men and absence of depression for women. In both 
men and women absence of an ApoE4 allele was also predictive of a return to normal 
cognitive functioning. As has previously been suggested by Forsell et al. 
28
 depressive 
symptomatology is an important risk factor both for MCI and progression to dementia; 
however, we note that whereas depressive symptomatology increases the likelihood of a 
diagnosis of MCI for both men and women, it is only predictive of progression to dementia in 
women. The study has a number of short-comings. As already mentioned above, the time to 
follow-up may have been too short for slowly evolving cases of dementia.  Analysis 
according to MCI sub-type was not carried out as it was felt that the valid diagnosis of an 
isolated domain-specific cognitive impairment would require a more sophisticated clinical 
battery.  
 
In conclusion this study highlights the high prevalence and heterogeneity of MCI. As the 
majority of subjects identified at base-line were observed at follow-up to have persistent 
cognitive deficits or dementia, we conclude that the MCI-R algorithm has been relatively 
discriminating given the large number of potential confounders which were identified and the 
variable health status of subjects. Subjects returning to normal may, however, be considered 
as false positives. It may be useful in future refinements of the MCI algorithm for population 
studies to take into account the characteristics of this group. The present study has not only 
identified a large range of characteristics of MCI which have not previously been taken into 
account, but has also shown gender differences; notably cerebro- and cardio-vascular risk 
factors and diabetes for men and poor subjective health, insomnia and social isolation for 
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women, as well as lower rate HRT use. Depressive symptomatology is associated with a 
diagnosis of MCI for both sexes, but appears “benign” for men in that it is not associated with 
a poor prognosis. Finally, some potentially reversible risk factors for progression to dementia 
were identified, which were not the same for men and women (notably stroke in men and sub-
clinical depression and anticholinergic medication use in women). These factors should be 
taken into account in the development of gender specific clinical intervention programs for 
MCI.  
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Table 1: Differences between subjects classified as MCI at base-line and subjects 
without cognitive impairment both at base-line and follow-up (normal group) 
 
MCI subjects 
(n=2879)
Normal subjects
(n=4013)
Significance *
Age  mean (SD) 74.6 (5.7) 73.1 (4.9) <0.01
Sex (women) % 64.6 56.6 <0.01
Education level %
low 24.7 22.5 <0.01
medium 62.2 54.2
high 13.1 24.3
Hypertension (blood pressure cut off 
140/90 or antihypertensive  treatment) % 78.6 76.5 0.04
Hypercholesterolemia 
(cholesterol 6.2mmol or treatment) % 59 57.2 0.15
Diabetes mellitus 11 9 <0.01
Head trauma  % 7.5 7.2 0.21
All cardiovascular antecedents 10 7.7 <0.01
Stroke % 5.1 2.8 <0.01
Asthma % 8.5 7.5 0.13
Depression
Current major depression % 2.4 1.6 <0.01
Depressive symptomatology % 16 10.3 <0.01
Subthreshold depression % 9.2 4.6 <0.01
Antidepressive medication use % 9.2 4.6 <0.01
APOE4 genotype (%presence) 20.6 19.5 0.29
Nart (IQ) mean (SD) 21.1 (6.5) 24.3 (5.4) <0.01
Anticholinergic medication % 10.1 5.5 <0.01
 At least 2 cups coffee/day % 65.8 67.9 0.03
Tobacco use (packet/year) mean(SD) 7.4 (16.4) 8.6 (16.6) <0.01
Alcohol use % 78.8 81.4 <0.01
Physical activity % 31.5 36.5 <0.01
Good subjective health % 94.2 97 <0.01
Herpes % 30.7 30.1 0.57
Insomnia % 28.5 21.8 <0.01
BMI >27 % 35.4 31 <0.01
Appetite loss % 14.2 10.7 <0.01
Social isolation % 37.6 35.8 0.06
Difficulty with at least 1 IADL  % 12 7.8 < 0.01
Anaesthesia % 34.6 32 0.02
Hospitalisation cancer % 1.4 1.6 0.54
Hormonal Replacement Therapy 
(past or current) women % 30.2 33 0.06
* Student T Test or Chi-deux test as appropriate + 
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Table 2: Principal socio-demographic and clinical characteristics differentiating normal and 
MCI subjects at base-line adjusting for confounders (logistic regression)  
 
Men 
Variables Significance OR 95 % CI
Anticholinergic medication <0.01 2.26 1.44-3.56
Depressive symptomatology <0.01 1.69 1.27-2.25
stroke <0.01 1.54 1.01-1.36
Diabetes 0.01 1.45 1.09-1.94
BMI>27 0.01 1.40 1.14-1.72
Age (continuous) 0.02 1.02 1.01-1.04
Results are adjusted by centre  
 
Women 
 
Variables Significance OR 95 % CI
Poor subjective health 0.04 1.55 1.02-2.37
Anticholinergic medication 0.04 1.47 1.12-1.91
IADL deficit 0.01 1.40 1.07-1.83
Depressive symptomatology 0.04 1.26 1.00-1.59
Social isolation 0.01 1.21 1.04-1.42
Insomnia 0.03 1.21 1.00-1.43
Results are adjusted by centre  
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 Table 3: Socio-demographic and clinical characteristics of  MCI  subjects according to 
clinical status four years later (dementia, MCI, return to normal cognitive functioning) 
 
 
group 1
MCI to 
dementia
(n=189)
group 2 
MCI to 
MCI
(n=1626)
group 3 
MCI to 
normal
(n=1064)
1 vs 3 1 vs 2 2 vs 3
Age  mean (SD) 78.5 (5.2) 74.1 (5.3) 73.3 (5.2) <0.01 <0.01 <0.01
Sex (women) % 58.7 66.7 62.3 NS 0.02 NS
Education level %
low 41.5 23.7 23.2
medium 42.0 66.0 60.1 <0.01 <0.01 <0.01
high 16.5 10.3 16.7
Hypertension % 82.5 78.2 76.6 0.04 NS NS
Hypercholesterolemia % 54.3 60.3 57.7 NS NS NS
Diabetes mellitus % 17.2 11 10 <0.01 0.02 NS
Head trauma  % 7 7.8 7 NS NS NS
All Cardiovascular antecedent % 17 9.8 8.6 <0.01 0.02 NS
Stroke % 11.7 5.1 3.8 <0.01 <0.01 NS
Asthma % 10.6 9.2 7.1 NS NS 0.04
Depression
Current major depression % 3.1 3.1 1.6 NS NS 0.03
high depressive  symptomatology % 25.7 17.3 12 <0.01 <0.01 0.01
Subclinical depression % 18.1 13.2 10 <0.01 <0.01 <0.01
Antidepressive medication use % 19 9.7 7 <0.01 <0.01 0.01
APOE4 genotype ( % presence) 32.1 21 16.7 0.01 <0.01 <0.01
Nart (IQ) mean (SD) 19.5 (7.3) 21 (6.3) 22.7 (5.8) <0.01 <0.01 <0.01
Anticholinergic medication % 16 11 7.6 <0.01 0.04 0.01
At least 2 cups coffee/day % 58.8 66 66.7 NS NS NS
Alcohol use % 78.8 77.7 80.3 NS NS NS
Tobacco use (packet/year) mean(SD) 7.8 (19.2) 7.3 (16.5) 7.5 (15.8) NS NS NS
Good subjective health % 87.2 93.8 95.1 <0.01 <0.01 0.04
Herpes % 29.1 32 29.2 NS NS NS
Insomnia % 33.1 30 25.4 NS NS 0.02
BMI >27 % 30.8 37 34.4 NS NS NS
Appetite loss % 23 15.6 10.6 <0.01 <0.01 <0.01
Social isolation % 43.8 38.6 35.2 0.05 NS NS
Difficulty with at least 1 IADL % 33.3 12.1 8.2 <0.01 <0.01 0.03
Anaesthesia % 31.4 34 36 NS NS NS
Hospitalisation cancer % 1.6 1.3 1.5 NS NS NS
Hormonal Replacement Therapy 
(past or current) women % 18.6 29.6 33 <0.01 0.03 NS
* Student T Test or Chi-deux test as appropriate  
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Table 4: Significant determinants of four-year outcome (dementia) for MCI men and women 
by logistic regression adjusting for confounders 
 
Men  
 
Variables Significance OR 95 % CI
APOE4 allele <0.01 3.15 1.74-5.70
Stroke 0.02 2.84 1.17-6.85
Low education level <0.01 2.26 1.25-4.06
IADL deficit 0.03 2.20 1.07-4.49
Age <0.01 1.16 1.10-1.21
Results are adjusted by centre  
 
 
Women  
 
Variables Significance OR 95 % CI
IADL deficit <0.01 3.51 2.09-5.89
APOE4 allele <0.01 2.34 1.38-3.96
Low education level <0.01 2.16 1.31-3.56
Subclinical depression 0.03 1.95 1.06-3.58
Anticholinergic medication 0.04 1.78 1.00-3.18
Age <0.01 1.14 1.09-1.19
Results are adjusted by centre  
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